Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.

Dadu, Ramona; Shah, Komal; Busaidy, Naifa L; Waguespack, Steven G; Habra, Mouhammad A; Ying, Anita K; Hu, Mimi I-Nan; Bassett, Roland L; Jimenez, Camilo; Sherman, Steven I; Cabanillas, Maria E.

doi:10.1210/jc.2014-2246

Record: found
Abstract: found
Article: not found

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.

Author(s): Ramona Dadu ¹ , Komal Shah , Naifa L Busaidy , Steven G Waguespack , Mouhammad A Habra , Anita K Ying , Mimi I Hu , Roland Bassett , Camilo Jimenez , Steven I Sherman , Maria E Cabanillas

Publication date (Electronic): Jan 2015

Journal: The Journal of clinical endocrinology and metabolism

Read this article at

ScienceOpenPublisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Clin. Endocrinol. Metab.

Title: The Journal of clinical endocrinology and metabolism

ISSN (Electronic): 1945-7197

ISSN (Print): 0021-972X

Publication date (Electronic): Jan 2015

Volume: 100

Issue: 1

Affiliations

[1 ] Departments of Endocrine Neoplasia and Hormonal Disorders (R.D., N.L.B., S.G.W., M.A.H., A.K.Y., M.I.H., C.J., S.I.S., M.E.C.), Diagnostic Radiology (K.S.), and Biostatistics (R.B.), The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030.

Article

DOI: 10.1210/jc.2014-2246

PMC ID: 4283003

PubMed ID: 25353071

SO-VID: 7dc5408d-67f8-42ac-bcde-37db948db1a2

History

Data availability:

Comments

Comment on this article

Cited by 45

See all cited by

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.

Read this article at

Abstract

Related collections

Bioscientifica Open Endocrinology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 26

Cited by 45